Vimta Labs Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹112 Cr +9.8% YoYSee revenue, profit and what management said. You are viewing Q1 FY26.
VL

Vimta Labs Ltd

Q1 FY26Healthcare Services

Vimta Labs Q1 FY26 earnings call: Revenue & Margins

Q1 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹98Cr
+30.7% YoY
+4.3% QoQ
Net profit
₹19Cr
+58.3% YoY
+5.6% QoQ
Margin
35%
0 pp YoY
0 pp QoQ
Price₹630
Market cap₹2.8K Cr
P/E34.1

The short version

Vimta Labs expects healthy growth, targeting a 15% to 20% CAGR, which is about double the industry growth rate. Vimta Labs aims to achieve an annual revenue run rate of INR 120-125 crores by end of the current year, targeting INR 500 crore annually.

From Vimta Labs Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Vimta Labs expects healthy growth, targeting a 15% to 20% CAGR, which is about double the industry growth rate.
  • The company aims to double its turnover within the next 3 years based on current and planned capex.
  • Growth drivers include pharmaceutical services (preclinical, clinical research, cGMP analytical), electrical and electronics testing (a sunrise industry), and biologics contract research and development services expected to commercialize from Q1 FY 2027.
  • Export revenue, mainly from pharmaceutical services, is growing strongly and expected to sustain.
  • Expansion in laboratory infrastructure will support organic growth for the next 5 years without need for additional space.

2 more points from Vimta Labs Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Vimta Labs Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • FY '26 planned capex: INR 80-100 crores, with INR 26 crores already spent in Q1 FY '26.
  • Approximately 30% of FY '26 capex is earmarked for biologics contract research and development services setup.
  • Remaining capex aims at purchasing new equipment and replacing existing equipment.
  • Past capex majorly spent on new facility construction (over INR 60 crores in previous year).
  • Investments also focused on digitizing and automating laboratory processes.

2 more points from Vimta Labs Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
Rev 1Mar 3
3
Rev 2Mar 1
4
Rev 2Mar 1
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Vimta Labs Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • The clinical trial pipeline is described as "quite encouraging" with a decent number of inquiries received in the last quarter.
  • A couple of clinical trial projects are in the final stages of conversion, with others also looking promising.
  • The company is focusing on building a track record in clinical trials, which is a new area for them.
  • Overall demand across sectors including pharma, food, and electronics is positive.

2 more points from Vimta Labs Ltd's call on order book

Create a free account to keep reading this call

Vimta Labs Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Vimta Labs Ltd Q1 FY26 results — key figures

Vimta Labs Ltd Q1 FY26 reported results vs Q1 FY25, ₹ crore
₹ CrQ1 FY26Q1 FY25YoYQ4 FY25QoQ
Revenue9875+30.7%94+4.3%
Operating profit (EBITDA)3426+30.8%33+3%
Operating margin35%35%0 pp35%0 pp
Profit before tax2517+47.1%250%
Net profit (PAT)1912+58.3%18+5.6%
EPS (₹)4.242.77+53.1%4.12+2.9%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹112 Cr, net profit ₹21 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Healthcare Services this season

  • Aster DM Quality (Q1 FY26)

    Recent quarters saw subdued volume growth due to leadership changes and seasonal effects, but an 8% volume growth was achieved in Q1 FY26, improving from 2% in…

  • Dr Agarwal's Hea (Q1 FY26)

    70 crores via preferential allotment to AEHL for CAPEX plans, particularly the flagship facility at Cathedral Road, indicating capacity and service…

  • Syngene International (Q1 FY26)

    Operating EBITDA grew 21% YoY in Q1 FY '26 with margins rising to ~24% from 22% last year. Key concall takeaways from Syngene International Ltd's Q1 FY26…

  • Yatharth Hospital & Trauma Care Services (Q1 FY26)

    International patient business is growing but will remain around 10% of revenue, positively impacting ARPOB without hurting margins. Key concall takeaways from…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Vimta Labs Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Vimta Labs Ltd Q1 FY26 results?

Vimta Labs expects healthy growth, targeting a 15% to 20% CAGR, which is about double the industry growth rate. Vimta Labs aims to achieve an annual revenue run rate of INR 120-125 crores by end of the current year, targeting INR 500 crore annually.

What is Vimta Labs Ltd share price analysis?

Vimta Labs Ltd currently shows a neutral. The stock trades at a P/E of 34.1 with a market cap of ₹2,757 Cr. Investors should review the full earnings analysis for detailed insights.

Is Vimta Labs Ltd planning capital expenditure?

FY '26 planned capex: INR 80-100 crores, with INR 26 crores already spent in Q1 FY '26.

Keep Vimta Labs Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.